1. Name Of The Medicinal Product
MOVIPREP, powder for oral solution
2. Qualitative And Quantitative Composition
The ingredients of MOVIPREP are contained in two separate sachets.
Sachet A contains the following active substances: | |
|
|
|
|
|
|
|
|
Sachet B contains the following active substances: | |
|
|
|
|
The concentration of electrolyte ions when both sachets are made up to one litre of solution is as follows: | |
|
|
|
|
|
|
Potassium |
|
Ascorbate |
|
This product contains 0.233g of aspartame per sachet A.
For a full list of excipients, see section 6.1.
3. Pharmaceutical Form
Powder for oral solution.
Free flowing white to yellow powder in Sachet A.
Free flowing white to light brown powder in Sachet B.
4. Clinical Particulars
4.1 Therapeutic Indications
For bowel cleansing prior to any clinical procedures requiring a clean bowel e.g. bowel endoscopy or radiology.
4.2 Posology And Method Of Administration
Adults and elderly: A course of treatment consists of two litres of MOVIPREP. It is strongly recommended that one litre of clear liquid, which may include, water, clear soup, fruit juice without pulp, soft drinks, tea and/or coffee without milk, is also taken during the course of treatment.
A litre of MOVIPREP consists of one 'Sachet A' and one 'Sachet B' dissolved together in one litre of water. This reconstituted solution should be drunk over a period of one to two hours. This should be repeated with a second litre of MOVIPREP.
This course of treatment can be taken:
either divided as one litre of MOVIPREP in the evening before and one litre of MOVIPREP in the early morning of the day of the clinical procedure, or, in the evening preceding the clinical procedure.
There should be at least one hour between the end of intake of fluid (MOVIPREP or clear liquid) and the start of colonoscopy.
No solid food should be taken from the start of the course of treatment until after the clinical procedure.
Children: Not recommended for the use in children below 18 year of age, as MOVIPREP has not been studied in the paediatric population.
4.3 Contraindications
Do not use in patients with known or suspected:
- gastrointestinal obstruction or perforation
- disorders of gastric emptying (e.g. gastroparesis)
- ileus
- phenylketonuria (due to presence of aspartame)
- glucose-6-phosphate dehydrogenase deficiency (due to presence of ascorbate)
- hypersensitivity to any of the ingredients
- toxic megacolon which complicates very severe inflammatory conditions of the intestinal tract including Crohn's disease and ulcerative colitis.
Do not use in unconscious patients.
4.4 Special Warnings And Precautions For Use
Diarrhoea is an expected effect resulting from the use of MOVIPREP.
MOVIPREP should be administered with caution to fragile patients in poor health or patients with serious clinical impairment such as:
- impaired gag reflex, or with a tendency to aspiration or regurgitation
- impaired consciousness
- severe renal insufficiency (creatinine clearance <30ml/min)
- cardiac impairment (NYHA grade III of IV)
- dehydration
- severe acute inflammatory disease
The presence of dehydration should be corrected before the use of MOVIPREP.
Semi-conscious patients or patients prone to aspiration or regurgitation should be closely observed during administration, especially if this is via a nasogastric route.
If patients develop any symptoms indicating shifts of fluid/electrolytes (e.g. oedema, shortness of breath, increasing fatigue, cardiac failure), plasma electrolytes should be measured and any abnormality treated appropriately.
In debilitated fragile patients, patients with poor health, those with clinically significant renal impairment and those at risk of electrolyte imbalance, the physician should consider performing a baseline and post-treatment electrolyte and renal function test.
If patients experience symptoms such as severe bloating, abdominal distention, abdominal pain or any other reaction which makes it difficult to continue the preparation, they may slow down or temporarily stop consuming MOVIPREP and should consult their doctor.
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
Oral medication should not be taken within one hour of administration of MOVIPREP as it may be flushed from the gastro-intestinal tract and not absorbed. The therapeutic effect of drugs with a narrow therapeutic index or short half-life may be particularly affected.
4.6 Pregnancy And Lactation
There are no data on the use of MOVIPREP during pregnancy or lactation and it should only be used if considered essential by the physician.
4.7 Effects On Ability To Drive And Use Machines
There is no known effect on the ability to drive and use machines.
4.8 Undesirable Effects
Diarrhoea is an expected outcome of bowel preparation. Due to the nature of the intervention, undesirable effects occur in the majority of patients during the process of bowel preparation. Whilst these vary between preparations, nausea, vomiting, bloating, abdominal pain, anal irritation and sleep disturbance commonly occur in patients undergoing bowel preparation.
As with other macrogol containing products, allergic reactions including rash, urticaria, pruritus, angioedema and anaphylaxis are a possibility.
Data from clinical studies are available in a population of 825 patients treated with MOVIPREP in which undesirable effect data were actively elicited. Additionally, adverse events reported in postmarketing are included.
The frequency of adverse reactions to MOVIPREP is defined using the following convention:
Very common
Common
Uncommon
Rare
Very rare < 1/10,000 (< 0.01%)
Not known (cannot be estimated from the available data)
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
| |
|
| |
|
|
|
|
|
|
|
|
|
|
| |
|
| |
|
|
|
4.9 Overdose
In case of gross accidental overdosage, where diarrhoea is severe, conservative measures are usually sufficient; generous amounts of fluid, especially fruit juices, should be given. In the rare event of overdose provoking severe metabolic derangement, intravenous rehydration may be used.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
Pharmacotherapeutic group: Osmotically acting laxative.
ATC code: A06A D
The oral administration of macrogol-based electrolyte solutions causes moderate diarrhoea and results in rapid emptying of the colon.
Macrogol 3350, sodium sulphate and high doses of ascorbic acid exert an osmotic action in the gut, which induce a laxative effect.
Macrogol 3350 increases the stool volume, which triggers colon motility via neuromuscular pathways.
The physiological consequence is a propulsive colonic transportation of the softened stools.
The electrolytes present in the formulation and the supplementary clear liquid intake are included to prevent clinically significant variations of sodium, potassium or water, and thus reduce dehydration risk.
5.2 Pharmacokinetic Properties
Macrogol 3350, is unchanged along the gut. It is virtually unabsorbed from the gastro-intestinal tract. Any macrogol 3350 that is absorbed is excreted via the urine.
Ascorbic acid is absorbed mainly at the small intestine level by a mechanism of active transport, which is sodium dependant and saturable. There is an inverse relationship between the ingested dose and the percentage of the absorbed dose. For oral doses between 30 and 180mg an amount of about 70-85% of the dose is absorbed. Following oral intake of up to 12g ascorbic acid , it is known that only 2g is absorbed.
After high oral doses of ascorbic acid and when plasma concentrations exceed 14mg/litre, the absorbed ascorbic acid is mainly eliminated unchanged in the urine.
5.3 Preclinical Safety Data
Preclinical studies provide evidence that macrogol 3350, ascorbic acid and sodium sulphate have no significant systemic toxicity potential.
No studies have been carried out on the genotoxicity, carcinogenicity or toxic effect on reproduction with this product.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Aspartame (E951)
Acesulfame Potassium (E950)
Lemon flavour containing maltodextrin, citral, lemon oil, lime oil, xanthan gum, vitamin E.
6.2 Incompatibilities
Not applicable
6.3 Shelf Life
|
|
|
|
6.4 Special Precautions For Storage
Sachets: Store below 25°C
Reconstituted Solution: Store below 25°C. The solution may be refrigerated. Keep the solution covered.
6.5 Nature And Contents Of Container
A paper / low density polyethylene / aluminium / low density polyethylene sachet containing 112g of powder ('sachet A') and a paper / low density polyethylene / aluminium / low density polyethylene sachet containing 11 g of powder ('sachet B'). Both sachets are contained in a transparent bag. One pack of MOVIPREP contains a single treatment of two bags.
Pack sizes of 1, 10, 40, 80, 160 and 320 packs of a single treatment. Hospital packs of 40 single treatments. Not all pack sizes may be marketed.
6.6 Special Precautions For Disposal And Other Handling
Reconstitution of MOVIPREP in water may take up to 5 minutes and is best performed by adding the powder to the mixing vessel first followed by the water. The patient should wait until all the powder has dissolved before drinking the solution.
After reconstitution in water MOVIPREP consumption may begin immediately or if preferred it may be cooled before use.
7. Marketing Authorisation Holder
Norgine BV
Hogehilweg 7, 1101CA Amsterdam ZO
The Netherlands
8. Marketing Authorisation Number(S)
PL: 20142/0005
9. Date Of First Authorisation/Renewal Of The Authorisation
19/01/2006 / 18/01/2011
10. Date Of Revision Of The Text
18/01/2011
No comments:
Post a Comment